| Literature DB >> 27642522 |
Rose M Ayoob1, Andrew L Schwaderer1.
Abstract
The most common acute glomerulonephritis in children is poststreptococcal glomerulonephritis (PSGN) usually occurring between 3 and 12 years old. Hypertension and gross hematuria are common presenting symptoms. Most PSGN patients do not experience complications, but rapidly progressive glomerulonephritis and hypertensive encephalopathy have been reported. This paper reports 17 patients seen in 1 year for PSGN including 4 with atypical PSGN, at a pediatric tertiary care center. Seventeen children (11 males), mean age of 8 years, were analyzed. Ninety-four percent had elevated serum BUN levels and decreased GFR. Four of the hospitalized patients had complex presentations that included AKI along with positive ANA or ANCAs. Three patients required renal replacement therapy and two were thrombocytopenic. PSGN usually does not occur as a severe nephritis. Over the 12-month study period, 17 cases associated with low serum albumin in 53%, acute kidney injury in 94%, and thrombocytopenia in 18% were treated. The presentation of PSGN may be severe and in a small subset have associations similar to SLE nephritis findings including AKI, positive ANA, and hematological anomalies.Entities:
Year: 2016 PMID: 27642522 PMCID: PMC5011525 DOI: 10.1155/2016/5163065
Source DB: PubMed Journal: Int J Nephrol
Patient demographics.
| Patient | Sex | Age (yr) | f/u time (yr) |
|---|---|---|---|
| 1 | M | 6 | <1 |
| 2 | M | 7 | <1 |
| 3 | M | 8 | 1 |
| 4 | F | 15 | 1 |
| 5 | F | 6 | <1 |
| 6 | M | 6 | <1 |
| 7 | M | 7 | 0 |
| 8 | F | 8 | 2 |
| 9 | M | 6 | <1 |
| 10 | M | 8 | 5 |
| 11 | F | 6 | 1 |
| 12 | M | 12 | 1 |
| 13 | M | 11 | <1 |
| 14 | F | 11 | <1 |
| 15 | F | 5 | <1 |
| 16 | M | 7 | <1 |
| 17 | M | 10 | <1 |
BP and urine findings during acute PSGN and at follow-up.
| Patient | BP (mmHg) | BP%∧ | Urine heme/RBCs per HPF | |||
|---|---|---|---|---|---|---|
| Initial | f/u | Initial | f/u | Initial | f/u | |
| 1 | 116/76 | 95 | NA | 409 | 79 | |
| 2 | 90/60 | 111/67 | 50 | 90 | 44 | Large |
| 3 | 119/86 | 107/69 | 95 | 95 | 1011 | Trace |
| 4 | 173/123 | 126/68 | 99 | 90 | LRG | Large |
| 5 | 119/72 | 107/65 | 99 | 90 | LRG | 28 |
| 6 | 109/74 | 109/74 | 90 | 90 | 401 | Large |
| 7 | 81/59 | 89/60 | 50 | 25 | 236 | Trace |
| 8 | 123/66 | 100/60 | 99 | 50 | 266 | Neg |
| 9 | 138/80 | 113/62 | 99 | 90 | 776 | Large |
| 10 | 118/73 | 118/65 | 95 | 75 | 307 | Neg |
| 11 | 114/76 | 95/60 | 95 | 75 | 1481 | Neg |
| 12 | 141/73 | 113/63 | 99 | 80 | 573 | Neg |
| 13 | 137/83 | 128/69 | 99 | 96 | 99 | Large |
| 14 | 131/92 | 104/67 | 99 | 50 | 247 | 15 |
| 15 | 149/106 | 104/70 | 99 | 85 | LRG | Mod |
| 16 | 127/53 | 113/59 | 99 | 89 | 117 | Mod |
| 17 | 136/74 | 116/65 | 99 | 95 | 23 | Small |
NA: not available; ∧BP% by age, height, and gender.
Serum lab results during acute PSGN and at follow-up.
| Patient | Creatine (mg/dL) | eGFR (mL/min/1.73 m2) | BUN | Albumin | C3 (mg/dL) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peak | f/u | Nadir | f/u | Peak | f/u | Peak | f/u | Initial | f/u | |
| 1 | 0.91 | 0.55 | 56 | 93 | 28 | 16 | 3.3 | 4.6 | 11 | 90 |
| 2 | 0.64 | 0.55 | 83 | 96 | 20 | NA | 3.8 | 3.8 | 42 | 97 |
| 3 | 7.03 | 0.56 | 8 | 104 | 120 | 21 | 2.6 | 4.4 | 29 | 110 |
| 4 | 1.39 | 0.87 | 48 | 75 | 36 | 15 | 3.2 | 3.7 | 17 | 127 |
| 5 | 0.8 | NA | 56 | NA | 18 | NA | 3.2 | NA | 15 | 123 |
| 6 | 0.7 | 0.45 | 74 | 115 | 22 | NA | 3.9 | NA | 20 | 137 |
| 7 | 0.67 | 0.48 | 73 | 102 | 26 | 8 | 2.6 | NA | 27 | 91 |
| 8 | 2.45 | 0.49 | 22 | 115 | 52 | 12 | 2.4 | 4.2 | 9 | 123 |
| 9 | 0.99 | 0.46 | 52 | 110 | 29 | 12 | 3.1 | 4.7 | 40 | 168 |
| 10 | 10.4 | 0.97 | 6 | 69 | 208 | 22 | 2.2 | 4.1 | 30 | 119 |
| 11 | 3.51 | 0.39 | 14 | 136 | 93 | 13 | 3.1 | 4.1 | 25 | 120 |
| 12 | 3.62 | 0.45 | 16 | 130 | 91 | NA | 2.5 | 4 | 7 | 123 |
| 13 | 1.64 | 0.58 | 40 | 114 | 82 | 13 | 2.8 | 4.4 | 6 | 139 |
| 14 | 1.8 | 0.78 | 36 | 75 | 92 | 14 | 3.1 | NA | 15 | 93 |
| 15 | 0.73 | 0.45 | 64 | 101 | 26 | 13 | 3.1 | NA | 12 | 125 |
| 16 | 3.43 | 0.45 | 16 | 119 | 105 | 12 | NA | NA | 11 | 93 |
| 17 | 1.29 | 0.48 | 48 | 128 | 46 | 21 | 4 | 4 | 21 | 114 |
NA: not available.
Patients with atypical PSGN.
| Pt | eGFR | BUN initial : peak | K+ initial : peak | % fluid overload | BP | RRT indication | % crescents | Serology | Atypical findings |
|---|---|---|---|---|---|---|---|---|---|
| 3 | 10 | 113 : 120 | 5.6 : 5.6 | 10.8 | 119/86 : 145/106 | AKI, fluid overload, anuria | 66% | ANA +1 : 160 | Thrombocytopenia |
| 10 | 6 | 208 : 208 | 6.1 : 6.1 | 1.9 | 118/73 : 131/85 | AKI, hyperK+ | 85% | ANA +1 : 80 | Seizures |
| 11 | 18 | 36 : 93 | 4.7 : 6.6 | 7.5 | 114/76 : 131/70 | No RRT, hyperK+, HTN responded to medical management | 30% | cANCA +1 : 20 | Mental status changes, neck mass |
| 12 | 24 | 64 : 91 | 4.0 : 5.8 | 12 | 141/73 : 159/106 | AKI, HTN urgency | None | ANA +1 : 160 | Thrombocytopenia |
Comparison of study patients with historical studies in poststreptococcal glomerulonephritis.
| Parameter | Study patients | Historical studies |
|
|---|---|---|---|
| BUN > 20 mg/dL | 16/17 (94%) | 18/45 (40%) [ |
|
| 48/138 (35%) [ |
| ||
| 21/35 (60%) [ |
| ||
| 36/46 (78%) [ | 0.26 | ||
|
| |||
| eGFR < 80 mL/min/1.73 m2 | 16/17 (94%) | 14/32 (44%) [ |
|
| 14/29 (48%) [ |
| ||
|
| |||
| Hypertensive complications | 7/17 (41%) | 13/50 (26%) [ | 0.38 |
| 10/35 (28%) [ | 0.55 | ||
∗ refers to statistical significance.